drug deliveryNovartis commits $3.2B to subcutaneous deliveryNovartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen’s technology for turning intravenous biologics into subcutaneous drugs. Behind the eye-catching figure is more than patient … more ➔
anti-obesityMenarini pays up to €726M for Chinese obesity drugItalian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every … more ➔
clinical dataTransgene cancer vaccine keeps patients relapse-free for three yearsFrench biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three … more ➔
licensingGSK bets $1.3B on KRAS-EGFR conjugate from HUTCHMEDGSK has licensed ex-China rights to HUTCHMED’s HMPL-A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to $1.295 billion (€1.12 … more ➔
FinancingNovaGo raises $30M to advance regenerative spinal cord therapySwiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its lead anti-Nogo-A antibody into a randomized proof-of-concept study in patients … more ➔
clinical dataNovartis breaks BTK losing streak in multiple sclerosisNovartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another important clinical win for a class of BTK inhibitors that has endured several … more ➔
licensingRoche reloads B-cell strategy with $1.53B Simcere dealRoche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a deal potentially worth $1.53 billion (€1.32 billion). more ➔
Neurodegenerative DisordersAmyl Tx raises €8.25M to develop universal neurodegeneration drugBelgian biotech Amyl Therapeutics has completed an €8.25 million Series A extension to fund work on its universal treatment for neurodegenerative diseases. more ➔
artificial intelligenceAdaptyv raises $40M for AI-run wet labsSwiss biotech Adaptyv has raised a $40 million (€34.5 million) Series A to expand its automated protein-testing labs, betting that wet-lab capacity will become a critical bottleneck as AI models generate … more ➔
NovartisCAR-TNovartis: Three deaths put CAR-T expansion into autoimmune diseases on holdNovartis has paused eight clinical trials of its CD19 CAR-T therapy rap-cel after three patients died from a severe immune reaction. The studies are evaluating the therapy in autoimmune and neurological … more ➔
Novartis